These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32583087)

  • 1. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.
    Villegas C; Poza M; Talayero P; Teller JMC; Zafra D; Garcia C; Vera E; Hidalgo M; Lopez N; Cuellar C; Zamanillo I; Íñiguez R; Paz-Artal E; Aguado JM; Martinez-Lopez J
    Ann Hematol; 2020 Dec; 99(12):2953-2956. PubMed ID: 32583087
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.
    Geng J; Wang F; Huang Z; Chen X; Wang Y
    Cytokine; 2021 Jul; 143():155544. PubMed ID: 33926774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroconversion and kinetic of anti SARS-COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection.
    Candoni A; Pizzano U; Fabris M; Curcio F; Fanin R
    Hematol Oncol; 2021 Aug; 39(3):428-431. PubMed ID: 33951220
    [No Abstract]   [Full Text] [Related]  

  • 4. SARS-CoV-2 multisystem inflammatory syndrome in an adult presenting with polyarthritis treated with anakinra.
    Chalasani V; Parameswaran P; Cherico A; Villgran V; Lowther H; Marco J
    Rheumatology (Oxford); 2022 Feb; 61(2):e33-e34. PubMed ID: 34508552
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.
    Franzetti M; Pozzetti U; Carugati M; Pandolfo A; Molteni C; Faccioli P; Castaldo G; Longoni E; Ormas V; Iemoli E; Piconi S
    Int J Infect Dis; 2020 Aug; 97():215-218. PubMed ID: 32422376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
    Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
    J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure.
    Direz G; Noël N; Guyot C; Toupance O; Salmon JH; Eschard JP
    Joint Bone Spine; 2012 Dec; 79(6):631. PubMed ID: 22841588
    [No Abstract]   [Full Text] [Related]  

  • 8. Interleukin-1RA Mitigates SARS-CoV-2-Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice.
    Xiong S; Zhang L; Richner JM; Class J; Rehman J; Malik AB
    Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2773-2785. PubMed ID: 34496633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.
    Aouba A; Baldolli A; Geffray L; Verdon R; Bergot E; Martin-Silva N; Justet A
    Ann Rheum Dis; 2020 Oct; 79(10):1381-1382. PubMed ID: 32376597
    [No Abstract]   [Full Text] [Related]  

  • 10. Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure.
    Brusasco C; Corradi F; Di Domenico A; Raggi F; Timossi G; Santori G; Brusasco V; ;
    Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33033151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
    Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032
    [No Abstract]   [Full Text] [Related]  

  • 12. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
    Kooistra EJ; Waalders NJB; Grondman I; Janssen NAF; de Nooijer AH; Netea MG; van de Veerdonk FL; Ewalds E; van der Hoeven JG; Kox M; Pickkers P;
    Crit Care; 2020 Dec; 24(1):688. PubMed ID: 33302991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs.
    Tran TA; Pariente D; Lecron JC; Delwail A; Taoufik Y; Meinzer U
    Arthritis Rheum; 2011 Dec; 63(12):4031-2. PubMed ID: 21898344
    [No Abstract]   [Full Text] [Related]  

  • 15. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands.
    Latourte A; Frazier A; Brière C; Ea HK; Richette P
    Ann Rheum Dis; 2013 May; 72(5):783-4. PubMed ID: 23291388
    [No Abstract]   [Full Text] [Related]  

  • 17. Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity?
    Abbate A; Canada JM; Van Tassell BW; Wise CM; Dinarello CA
    Int J Cardiol; 2014 Feb; 171(3):e125-6. PubMed ID: 24418290
    [No Abstract]   [Full Text] [Related]  

  • 18. Anakinra as a potential treatment for COVID-19.
    McCarthy MW
    Drugs Today (Barc); 2023 Mar; 59(3):107-112. PubMed ID: 36847621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment.
    Aomar-Millán IF; Salvatierra J; Callejas-Rubio JL; Raya-Álvarez E
    Reumatol Clin (Engl Ed); 2023 Feb; 19(2):120-121. PubMed ID: 35752586
    [No Abstract]   [Full Text] [Related]  

  • 20. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
    Cure E; Kucuk A; Cure MC
    Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.